Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- Cleveland Clinic lists potential conflicts of interest online
- HHS: 60 percent of DME companies banned by Medicare may keep billing
Poll
Featured Jobs
-
Tennessee Vascular/General Surgeon
StaffPointe, LLC - near Nashville , TN -
Michigan OBGYN
StaffPointe, LLC - south , MI -
California Internal Medicine
StaffPointe, LLC - near San Diego , CA -
Florida Dermatology
StaffPointe, LLC - northeast , FL -
Florida Orthopedic Surgeon CEx1143
StaffPointe, LLC - near Fort Meyers , FL
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
Grassley investigates Medicaid drug claims
Senator Chuck Grassley (D-Iowa) has begun investigating whether the Medicaid program is routinely paying for prescription drugs which haven't gone through the CMS approval process. Presently, to bill for Medicaid reimbursement, a drug maker must register its product with CMS, using an FDA-assigned code, and get an FDA certification that the drugs are kosher. Now, Grassley is attempting to find out whether some companies are billing for unapproved drugs using false codes--and more importantly, whether CMS is tracking these claims to monitor whether drugs are approved or not. Grassley would like to get a report from the FDA and CMS by next week explaining how they monitor the status of drugs billed for through Medicaid. He'd like to see the Department of Justice and the HHS Office of Inspector General go out and re-collect any improper payments.
To learn more about Grassley's issues:
- read this Kaiser Daily Health Policy Report piece
Related Articles:
Maine struggles with Medicaid billing system. Article
HHS grants improve Medicaid data management. Report
Related Stories
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- Competitive DME bidding could save CMS $1B
- Senators plan bill countering pharma detailing tactics
- Freeze proposed on Medicare audit program
- Trend: Hospitals improving informed consent process
- Vytorin, Avandia raise doubt on FDA approvals
- ME judge nixes law limiting prescribing data access
- Trend: Nursing homes big users of antipsychotic meds
- Senate may roll back 10 percent Medicare fee cut for MDs
- Trend: Physicians dispensing drugs in offices
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





